Please ensure Javascript is enabled for purposes of website accessibility

Will Moderna Stock Surge to $90?

By Joe Tenebruso - May 21, 2020 at 2:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts from one major investment bank say it will.

Moderna's (MRNA 2.58%) incredible 240% rise so far this year is just one stage of what will be a longer climb for the market-crushing stock.

So say analysts at Morgan Stanley, who reiterated their overweight rating on Moderna's shares Wednesday. The investment bank boosted its target price on the stock by a staggering 143%, to $90 per share, after the biotechnology company released positive data from its phase 1 study for mRNA-1273, its coronavirus vaccine candidate. Morgan Stanley's new price estimate represents potential gains of around 36% for investors, based on the price at which Moderna's shares are currently trading.

A person is pointing to an upwardly sloping. chart

Moderna's stock could still have plenty of upside thanks to its coronavirus vaccine candidate, according to Morgan Stanley's analysts. Image source: Getty Images.

Based on the preliminary data from the vaccine trial, Morgan Stanley now places the probability that it will be successful at 65%. "We believe both Moderna's ability to scale coupled with the promising early results positions them well to compete in the market," analyst Matthew Harrison said.

Moreover, the bank said that Moderna's recent move to raise cash at a higher valuation contributed to its target price increase. Most of the increase, however, was due to what Morgan Stanley views as a higher likelihood of success for Moderna's vaccine platform and an accelerated development timeline for its SARS-CoV-2 vaccine candidate.

Morgan Stanley says Moderna could potentially sell more than 1.6 billion doses of its novel coronavirus vaccine during the pandemic and in the years that follow.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$159.56 (2.58%) $4.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.